Suppr超能文献

相似文献

1
Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
Cell Rep. 2015 Oct 20;13(3):504-515. doi: 10.1016/j.celrep.2015.09.019. Epub 2015 Oct 8.
4
Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
J Proteome Res. 2020 Jan 3;19(1):194-203. doi: 10.1021/acs.jproteome.9b00495. Epub 2019 Nov 12.
5
Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Nature. 2016 Nov 10;539(7628):304-308. doi: 10.1038/nature20131. Epub 2016 Oct 26.
6
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
Blood. 2013 Jun 13;121(24):4925-9. doi: 10.1182/blood-2013-01-478412. Epub 2013 Apr 25.
7
Juvenile myelomonocytic leukaemia and Noonan syndrome.
J Med Genet. 2014 Oct;51(10):689-97. doi: 10.1136/jmedgenet-2014-102611. Epub 2014 Aug 5.
9
Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Mol Ther. 2023 Apr 5;31(4):986-1001. doi: 10.1016/j.ymthe.2023.01.030. Epub 2023 Feb 3.
10
Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.
Sci Signal. 2018 Jul 17;11(539):eaao5617. doi: 10.1126/scisignal.aao5617.

引用本文的文献

2
Decoding cancer etiology with cellular reprogramming.
Curr Opin Genet Dev. 2025 Feb;90:102301. doi: 10.1016/j.gde.2024.102301. Epub 2024 Dec 24.
3
Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia.
Med Oncol. 2024 Dec 9;42(1):25. doi: 10.1007/s12032-024-02549-5.
4
Biomarker Landscape in RASopathies.
Int J Mol Sci. 2024 Aug 6;25(16):8563. doi: 10.3390/ijms25168563.
5
Interconversion of Cancer Cells and Induced Pluripotent Stem Cells.
Cells. 2024 Jan 10;13(2):125. doi: 10.3390/cells13020125.
6
The role of GATA2 in adult hematopoiesis and cell fate determination.
Front Cell Dev Biol. 2023 Nov 14;11:1250827. doi: 10.3389/fcell.2023.1250827. eCollection 2023.
7
Merits and challenges of iPSC-derived organoids for clinical applications.
Front Cell Dev Biol. 2023 May 26;11:1188905. doi: 10.3389/fcell.2023.1188905. eCollection 2023.
9
Modeling (not so) rare developmental disorders associated with mutations in the protein-tyrosine phosphatase SHP2.
Front Cell Dev Biol. 2022 Nov 4;10:1046415. doi: 10.3389/fcell.2022.1046415. eCollection 2022.
10
Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development.
Stem Cells Transl Med. 2022 Nov 18;11(11):1123-1134. doi: 10.1093/stcltm/szac071.

本文引用的文献

2
Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
Blood. 2013 Jun 13;121(24):4925-9. doi: 10.1182/blood-2013-01-478412. Epub 2013 Apr 25.
4
Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Paediatr Drugs. 2012 Jun 1;14(3):157-63. doi: 10.2165/11631360-000000000-00000.
5
Kinetic analysis reveals the fate of a microRNA following target regulation in mammalian cells.
Curr Biol. 2011 Mar 8;21(5):369-76. doi: 10.1016/j.cub.2011.01.067. Epub 2011 Feb 25.
7
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia.
J Med Genet. 2010 Oct;47(10):686-91. doi: 10.1136/jmg.2010.076836. Epub 2010 Jun 12.
8
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome.
Nature. 2010 Jun 10;465(7299):808-12. doi: 10.1038/nature09005.
9
MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets.
Curr Drug Targets. 2010 Jul;11(7):801-11. doi: 10.2174/138945010791320872.
10
Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells.
Blood. 2010 Apr 8;115(14):2769-76. doi: 10.1182/blood-2009-07-234690. Epub 2010 Jan 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验